Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
No hype just what the science shows
Rapid weight loss with GLP-1 receptor agonists can also increase the risk of gallstone formation
There is no fixed conversion
Typical Weekly Dosing Schedule: Weeks 14: 1mg once weekly Weeks 58: 2mg once weekly Weeks 912: 4mg once weekly Weeks 1316: 6mg once weekly Weeks 1720: 8mg once weekly ( if needed and well tolerated) Weeks 21+: 1012mg once weekly (max range, based on response and provider guidance) Key Points: Administer once weekly only (not split dosing) Increase dose every 4 weeks based on tolerance If side effects occur, hold or step back to the previous dose Patients often see appetite suppression early, with metabolic effects increasing at higher doses Significant Weight Loss Helps reduce body fat by decreasing appetite and increasing feelings of fullness, leading to sustained calorie reduction
Novo Nordisk soon followed with Victoza (liraglutide) in 2010, a once-daily injection based on a modified version of human GLP-1
Findings GLP-1 receptor agonists and dual incretin agonists exert their therapeutic effects through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of glucagon release, appetite reduction, and slowing of gastric emptying
